Targanta Therapeutics
Proposed symbol TARG
IPO date not yet announced
Targanta Therapeutics is a biopharmaceutical company is developing new treatments for severe, drug-resistant bacterial infections, including those that attack the skin, blood, and bone. Its lead candidate is oritavancin, which may treat both skin and blood infections; the drug was first discovered by Eli Lilly and further developed by InterMune, from whom Targanta acquired the rights in 2005. The company plans to develop other antibiotics in addition to oritavancin; it is working on one earlier-stage candidate that may fight osteomyelitis, an inflammation of the bone caused by infection.
Proposed symbol TARG
IPO date not yet announced
Targanta Therapeutics is a biopharmaceutical company is developing new treatments for severe, drug-resistant bacterial infections, including those that attack the skin, blood, and bone. Its lead candidate is oritavancin, which may treat both skin and blood infections; the drug was first discovered by Eli Lilly and further developed by InterMune, from whom Targanta acquired the rights in 2005. The company plans to develop other antibiotics in addition to oritavancin; it is working on one earlier-stage candidate that may fight osteomyelitis, an inflammation of the bone caused by infection.
Labels: biotech, biotech investing, biotech ipo, biotech mill rumor
posted by doublezero at
2:20 PM
1 Comments:
Gold in Singapore, which normally determines price trend on the do-
mestic front, rose by 0.5 per cent to $1,201.60 an ounce. epicresearch.co
Post a Comment
Subscribe to Post Comments [Atom]
<< Home